195 related articles for article (PubMed ID: 27785946)
1. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
Dotsenko VV; Chigorina EA; Krivokolysko SG
Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
3. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
4. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
5. 1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284).
Gilbert EJ
Expert Opin Ther Pat; 2013 Aug; 23(8):1069-73. PubMed ID: 23837729
[TBL] [Abstract][Full Text] [Related]
6. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
[TBL] [Abstract][Full Text] [Related]
7. Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.
Zhang C
Discov Med; 2012 Sep; 14(76):189-97. PubMed ID: 23021373
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
Probst G; Xu YZ
Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
[TBL] [Abstract][Full Text] [Related]
9. [BACE1 inhibitors for the treatment of Alzheimer disease].
Tomita T
Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
[TBL] [Abstract][Full Text] [Related]
10. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
13. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
14. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
Sun X; Wang Y; Qing H; Christensen MA; Liu Y; Zhou W; Tong Y; Xiao C; Huang Y; Zhang S; Liu X; Song W
FASEB J; 2005 May; 19(7):739-49. PubMed ID: 15857888
[TBL] [Abstract][Full Text] [Related]
15. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
Das B; Yan R
CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Luo X; Yan R
Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
[TBL] [Abstract][Full Text] [Related]
18. Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
Naushad M; Durairajan SSK; Bera AK; Senapati S; Li M
Planta Med; 2019 Nov; 85(17):1316-1325. PubMed ID: 31618777
[TBL] [Abstract][Full Text] [Related]
19. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
20. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
